Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

Tread carefully, but certain factors make this speculative biotech play stand out.

Iovance (IOVA) Q1 2026 Earnings Transcript

It could just as well drop by 50% -- or more -- over the next 12 months.

This oncology specialist has proven innovative abilities.

If you decide to invest in this company, it's probably best to start small.

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Iovance (IOVA) Q4 2025 Earnings Call Transcript

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

The company is studying its approved drug for many other indications.

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.